Insights into Company Bills & Payments

Bharat Rasayan Limited

📍 New Delhi, Delhi, India Active NSE BHARATRAS CIN L24119DL1989PLC036264
Search companies

Key Metrics of Bharat Rasayan Limited

Revenue₹1,242 Cr▲ 5.9% YoYFY 2025-26
EBITDA₹222 Cr▲ 10.3% YoY
Net profit₹143 Cr▲ 14.3% YoY
Net worth₹1,249 Cr▲ 12.8% YoY

About Bharat Rasayan Limited

Company details

Registered office
1501 Vikram Tower Rajendra Place, New Delhi, In-dl, 110008
Listed
NSE: BHARATRAS · ₹936.80

Company summary

Entity details

CINL24119DL1989PLC036264
LEI code335800NXICUEZQ62XR71
State codeDL
PIN code110008
Current legal nameBHARAT RASAYAN LIMITED
Classification—
Listing statusListed (NSE: BHARATRAS)
Registration no.036264
Company age—
PAN—
CountryIndia
CityNew Delhi
StateDelhi
Current statusActive
Date of incorporation—
Registrar of companies—
Authorised capital—
Paid-up capital—
Employee count—

Compliance

Last AGM date—
Last balance sheet—
Next filing dueMGT-7 for FY 2025-26 · 29 Nov 2026

Industry classification

NIC code24119
Description of main activityManufacture of chemicals and chemical products (incl. pharmaceuticals)
Description of business activityManufacture of chemicals and chemical products (incl. pharmaceuticals)
SectorOther Industries · Discovered Companies

Share price · NSE: BHARATRAS

BHARATRAS on NSE

Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Sign in to continue See plans & pricing

Filing compliance

AGM for FY 2025-2630 Sep 2026 Statutory due date passed
AOC-4 for FY 2025-2630 Oct 2026 Statutory due date passed
MGT-7 for FY 2025-2629 Nov 2026 Statutory due date · 28 days left

Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.

Vendor checks & payment capacity

Sign in with access to company financials to review vendor evidence.

Credit ratings

CARE · 18 Dec 2025 — Other
Change in last 12 monthsNo change
Change since first rating on recordNo changesince Dec 2019
Rating actions110 up · 0 down
Liquidity (CARE)Strong

Rating history

Rating actions

DateAgencyActionLong termShort termOutlookRated amountRationale
18 Dec 2025CAREOther ———— View
09 Dec 2024CAREReaffirmed AA-A1+Stable₹250 Cr View
04 Apr 2024CAREReaffirmed AA-A1+Stable₹250 Cr View
27 Dec 2023CAREReaffirmed AA-A1+Stable₹350 Cr View
03 Jan 2023CAREReaffirmed AA-A1+Stable₹700 Cr View
25 May 2022CAREOther ———— View
23 Dec 2021CAREReaffirmed AA-A1+Stable₹250 Cr View
20 Dec 2021CAREReaffirmed AA-A1+Stable₹500 Cr View
30 Dec 2020CAREReaffirmed AA-A1+Stable₹400 Cr View
22 Dec 2020CAREOther ———₹50.0 Cr View
27 Dec 2019CAREReaffirmed AA-A1+Stable₹250 Cr View

Credit strengths (CARE, Dec 2025)

+ Integrated operations offering diversified product mix

BRL has a leading market position in many technical and intermediate products, including Lambda Cyhalothrin Technical, Meta phenoxy Benzaldehyde, Metribuzine Technical, Thiamethoxam (Insecticides) and Fipronil (Insecticides) among others. Though 1Complete definition of ratings assigned are available at www.careratings.com and other CARE Ratings Limited’s publications. 1 CARE Ratings Ltd. Press Release there is a slight product concentration risk, as BRL’s top three products accounts for ~25% of

+ Long-standing relationship with reputed customer base

The company supplies its products in local and overseas locations and has a long-standing relationship with reputed customers, including NISSEI Corporation, Syngenta Crop, Sumitomo Chemical Company Limited, Shanghai Agro tree Chemical Corporation Limited, and Rallis India Limited among others. BRL has 489 domestic registrations and 123 international registrations and has been exporting its products to over 24 countries across the globe. However, BRL is exposed to moderate client concentration ri

+ BRL also has long-standing associations with several reputed Japanese players and holds a 30:70 JV with Nissan Chemical

Corporation (NCC), which commenced commercial production in March 2023. The JV reported a total income of ₹373 crore in FY25 and ₹134 crore in H1FY26, with a profit after taxation (PAT) margin of 14% in FY25 and -6% in H1FY26. The negative PAT in H1FY26 was primarily considering a notional foreign exchange loss booked in the profit and loss account. Recovery in domestic demand in FY25 and strong financial risk profile

+ Recovery in domestic demand in FY25 and strong financial risk profile

In FY25, domestic demand recovered following above-average rainfall in key crop areas, supporting a rebound in operational performance after reporting a year-over-year degrowth due to weak industry-wide demand and a decline in prices driven by EL Nino and destocking by Chinese counterparts. In FY25, the company reported TOI of ₹1,183 crore (PY: ₹1,059.26 crore), PBILDT of ₹185.04 crore (₹ 132.32 crore), and a margin of 15.6% (PY:12.5%). The recovery continued into H1FY26, with TOI of ₹663.4

+ Experienced and resourceful promoters with long track record of operations in pesticides industry

BRL is part of the Bharat group; one of the leading manufacturers of technical grade pesticides in India and has been engaged in manufacturing and selling pesticides for over four decades. The company’s promoters have also extended support in terms of financial assistant to working capital requirements of the company in the past. The group’s directors are supported by a team of professionals with rich experience in varied spheres of business.

Credit challenges

− Profitability and sales susceptible to monsoon and climatic conditions

The pesticide/crop protection industry derives its sales from the agriculture sector , which highly depends on monsoons and incidence of fungal/pest attack on crops. Major fluctuations in total rainfall and its distribution affect the crop and overa ll productivity and has a direct correlation with sales and profitability of the pesticides i ndustry. However, the risk is partially mitigated through the company’s wide geographical presence covering over 21 states in India and over 24 countries, w

− Exposure towards highly regulated and competitive agrochemical industry

The pesticides industry is marked by heavy fragmentation with the absence of key player having sizeable market share. Intense competition leads to competitive pricing and lower margins. Traditionally, Indian players concentrated on marketing generic and off-patent products with little expenditure on research and development (R&D), while MNCs focused on developing patented molecules. BRL is supported by a dedicated R&D team that consistently works on developing innovative new products, ensuring

− Exposure towards foreign currency fluctuation risk

The Bharat Group is exposed to foreign currency fluctuation risk, as BRL’s export sales constitute ~around 26% of the company’s total sales in FY25 (PY: ~36.13%). BRL is also importing raw materials for manufacturing technical grade pesticides, as ~50% of the total purchases is imported, mainly from China (85% of total imports), Japan (12-14%) and balance from other countries. Thus, foreign exchange fluctuation risk is reduced, partially considering natural hedge available in the form of export

− Working capital intensive operations due to high inventory requirements and longer collection period

The pesticide industry requires high working capital investment due to high inventory holding and longer credit period on sales due to the commoditised products and seasonality factor. Average inventory holding remains at elevated level and stood ~101 days in FY25, though slightly reduced from 116 days in FY24. Providing extended credit is necessary to stimulate demand as farmers are left with little surplus money for purchasing pesticides after having invested in seeds, and fertilisers, among o

Could lead to an upgrade

Factors that could individually or collectively lead to positive rating action/upgrade: • The company’s ability to enhance its scale of operations over ₹1,400 crore and PBILDT margin over 15% on a sustained basis.

Could lead to a downgrade

Factors that could individually or collectively lead to negative rating action/downgrade: • Significant increase in the working capital cycle on a sustained basis impacting BRL’s

Agency-reported financials (CARE, 18 Dec 2025)

MetricMarch 31, 2024March 31, 2025H1FY26
Total operating income₹1,059 Cr₹1,183 Cr₹663 Cr
PBILDT₹132 Cr₹185 Cr₹102 Cr
PAT₹95.51 Cr₹141 Cr₹67.34 Cr
Overall gearing (times)0.08×0.07×—
Interest coverage (times)44.68×38.19×45.11×
Revenue growth (YoY)—11.7%—
EBITDA margin12.5%15.6%15.4%
Implied interest cost (EBITDA ÷ coverage)₹2.96 Cr₹4.85 Cr₹2.27 Cr
PAT margin9.0%11.9%10.2%

Borrowings & rated debt

Rated borrowing limits (latest)₹250 Cr
Peak rated limits₹700 CrJan 2023 · CARE
Limits raised0 times1 new facility rated

Rated limits over time

Facility mix

Rated facilities

FacilityTypePreviousCurrentChangeRatingActionAgency
Long-term bank facilitiesWorking capital & bank lines—₹149 Cr— AA- (Stable)ReaffirmedCARE
Short-term bank facilitiesWorking capital & bank lines—₹101 Cr— A1+ReaffirmedCARE

CARE ratings on record (checked 22 Oct 2026)

InstrumentAmountRating
BG/LC₹101 CrCARE A1+
Cash Credit₹149 CrCARE AA-; Stable
Commercial Paper (Carved out)—Withdrawn
Commercial Paper (Standalone)—Withdrawn
Term Loan—Withdrawn

Lenders

Fund-based - LTCash CreditHDFC Bank Ltd.
Fund-based - LTCash CreditICICI Bank Ltd.
Fund-based - LTCash CreditState Bank of India
Non-fund-based - STBG/LCHDFC Bank Ltd.
Non-fund-based - STBG/LCICICI Bank Ltd.
Non-fund-based - STBG/LCState Bank of India

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26

Indicative long-term—
Indicative short-term—
Score—
LiquidityStrongAgency: Strong
DirectionStable
CARE rating · Dec 2025—

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

DefaultNo default on record
Issuer cooperationCooperating
Credit enhancementNone – standalone rating
Next action stable or better (model)73%
Information on file78% · missing: Capex / investment plans, Auditor details

Indicative assessment from public data using the published methodology factors; not a credit rating.

Borrowing & funding lifecycle

⬇ PDF report⬇ Excel
Can it borrow more?Further bank funding difficult Next rating action stable or better: 57% (At risk of downgrade) · ML model on 6893 rating histories, AUC 0.653
Rated limits—
Not yet allocated—
Extra debt within 2.5× EBITDA—
Interest coverage45.11×
Limit utilisation—
Open bank charges0 · —
  • Credit outlook model: 57% chance the next rating action is stable or better
  • Interest coverage 45.11×

Rated limits by facility

Timeline

18 Dec 2025 CARE other: — CARE rationale
18 Dec 2025 Cash & liquid funds ₹285.51 cr
From the report

The company has a strong liquidity position, reflected in total liquidity of ₹285.51 crore, comprising ₹55 crore in cash and ₹230 crore in mutual funds, against a total debt of ₹85.22 crore as on March 31, 2025.

CARE rationale
18 Dec 2025 Cash & liquid funds ₹124.64 cr
From the report

The company’s liquidity stood at ₹285.51 crore as on March 31, 2025 (against total debt of ₹85.22 crore) comprising of ₹230.1 crore investments in mutual funds and ₹55.41 crore in cash and cash equivalents, which increased from total liquidity of ₹124.64 crore as on March 31, 2024, owing to healthy cash generation and faster turnaround on y-o-y basis as operating cycle reduced to 189 days in FY25 from 212 days in FY24.

CARE rationale
09 Dec 2024 CARE reaffirmed: AA- (Stable)Rated limits ₹250 cr CARE rationale
09 Dec 2024 Cash & liquid funds ₹32.43 cr
From the report

The company’s cash and cash equivalents stood at ₹32.43 crore as on March 31, 2024, which increased to ₹40.56 crore as on September 30, 2024.

CARE rationale
09 Dec 2024 Average working-capital utilisation 1.58%
From the report

Its unutilised fund-based bank lines are more-than-adequate to meet its incremental working capital needs over the next one year as the average utilisation for the trailing 12 months ending October 2024 stood at only 1.58%.

CARE rationale
04 Apr 2024 CARE reaffirmed: AA- (Stable)Rated limits ₹250 cr CARE rationale
04 Apr 2024 New borrowing arranged (commercial paper)
From the report

Stable Reaffirmed Short-term bank facilities 101.00 CARE A1+ Reaffirmed Commercial paper (standalone) - - Withdrawn Commercial paper (carved out)* - - Withdrawn Details of instruments/facilities in Annexure-1. *Carved out of sanctioned working capital limits of the company Rationale and key rating drivers The reaffirmation in the ratings assigned to the bank facilities of Bharat Rasayan Limited (BRL) continues to derive strengthfrom the long track record of the promoters in the pesticides industry and group’s integrated operations marked by presence across the entire value chain of the pestici

CARE rationale
04 Apr 2024 New borrowing arranged (commercial paper)
From the report

CARE Ratings Limited (CARE) has withdrawn the outstanding rating of CARE A1+ assigned to the commercial paper (CP) issue of BRL with immediate effect, as the company has not availed the aforementioned CP instruments rated by CARE and there is no amount outstanding under the said instruments as on date.

CARE rationale
04 Apr 2024 Cash & liquid funds ₹70 cr
From the report

Liquidity: Strong The liquidity is marked by healthy expected cash accruals of close to ₹70 crore in FY24 against zero debt repayment obligations and liquid investments to the tune of ₹91.54 crore as on March 28, 2024, largely held in the form of SBI mutual funds.

CARE rationale
27 Dec 2023 CARE reaffirmed: AA- (Stable)Rated limits ₹350 cr CARE rationale
27 Dec 2023 New borrowing arranged (commercial paper)
From the report

Stable Reaffirmed Short-term bank facilities 101.00 CARE A1+ Reaffirmed Commercial paper 50.00 CARE A1+ Reaffirmed Commercial paper (Carved out)* 50.00 CARE A1+ Reaffirmed Details of instruments/facilities in Annexure-1. *Carved out of sanctioned working capital limits of the company Rationale and key rating drivers The reaffirmation in the ratings assigned to the bank facilities of Bharat Rasayan Limited (BRL) continues to derive strength from the long track record of the promoters in the pesticides industry and group’s integrated operations marked by presence across the entire value chain of

CARE rationale
27 Dec 2023 Cash & liquid funds ₹70 cr
From the report

Liquidity: Strong The liquidity is marked by healthy expected cash accruals of close to ₹70 crore in FY24 against zero debt repayment obligations and liquid investments to the tune of ₹110.28 crore as on September 30, 2023, largely held in the form of SBI mutual funds (SBI overnight debt fund; no lock-in period).

CARE rationale
27 Dec 2023 New borrowing arranged: ₹79 cr (term loans)
From the report

Its unutilised fund-based bank lines of more than ₹79 crore as on September 30, 2023 are more-than-adequate to meet its incremental working capital needs over the next one year (average utilisation remained low around 18-20% for trailing 12 months ending with September 30, 2023, against sanctioned limit of ₹149.00 crore).

CARE rationale
27 Dec 2023 Average working-capital utilisation 20%
From the report

Its unutilised fund-based bank lines of more than ₹79 crore as on September 30, 2023 are more-than-adequate to meet its incremental working capital needs over the next one year (average utilisation remained low around 18-20% for trailing 12 months ending with September 30, 2023, against sanctioned limit of ₹149.00 crore).

CARE rationale
03 Jan 2023 CARE reaffirmed: AA- (Stable)Rated limits ₹700 cr CARE rationale
25 May 2022 CARE other: — CARE rationale
23 Dec 2021 CARE reaffirmed: AA- (Stable)Rated limits ₹250 cr CARE rationale
20 Dec 2021 CARE reaffirmed: AA- (Stable)Rated limits ₹500 cr CARE rationale
30 Dec 2020 CARE reaffirmed: AA- (Stable)Rated limits ₹400 cr CARE rationale
22 Dec 2020 CARE other: —Rated limits ₹50 cr CARE rationale
27 Dec 2019 CARE reaffirmed: AA- (Stable)Rated limits ₹250.32 cr CARE rationale

Lender names, bank charges and audited borrowings are part of Premium.

Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.

Registered office and contact

Registered office1501 VIKRAM TOWER RAJENDRA PLACE, NEW DELHI, IN-DL, 110008
GSTIN—
Email—
Website—
Members / shareholders—

Directors and key people

Directors are read from the MGT-7 annual return and AOC-4 signatories.

Charges (secured borrowings)

0 registered charges. Lenders, amounts and dates are part of the premium plan.

Statutory auditors

Auditors are read from the AOC-4 auditor's report section.

Business activities and related parties

Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.

Filings

No filings on record yet.